Also known as: Perlstein Lab PBC
Perlara: building the YC for rare disease parents
Company is active
Event Year: 2016
Company is active
Event Year: 2016
Perlara initially operated as Perlara 1.0 (February 2014 - February 2019), pioneering early-stage research and development joint ventures known as PerlQuests. These ventures involved close collaboration with highly motivated rare disease families, companies, and impact investors. The core strategy revolved around screening gene-edited patient avatars to identify existing drugs that could be repurposed for rare disease treatments. This process aimed to develop a predictive R&D engine called ArkBase.
The monetization strategy for programs stemming from ArkBase predictions involved selectively spinning out asset-centric clinical development companies (NewCos).
Perlara 1.5 (March 2019 - April 2020) marked a transition to a lean, one-person virtual clinical development company. During this phase, repurposing trials for epalrestat and aripiprazole were initiated at the Mayo Clinic to treat PMM2-CDG and NGLY1-CDDG, respectively.
Perlara 2.0 (May 2020 onwards) envisions a decentralized and distributed biotech model.
Perlara initially operated as Perlara 1.0 (February 2014 - February 2019), pioneering early-stage research and development joint ventures known as PerlQuests. These ventures involved close collaboration with highly motivated rare disease families, companies, and impact investors. The core strategy revolved around screening gene-edited patient avatars to identify existing drugs that could be repurposed for rare disease treatments. This process aimed to develop a predictive R&D engine called ArkBase.
The monetization strategy for programs stemming from ArkBase predictions involved selectively spinning out asset-centric clinical development companies (NewCos).
Perlara 1.5 (March 2019 - April 2020) marked a transition to a lean, one-person virtual clinical development company. During this phase, repurposing trials for epalrestat and aripiprazole were initiated at the Mayo Clinic to treat PMM2-CDG and NGLY1-CDDG, respectively.
Perlara 2.0 (May 2020 onwards) envisions a decentralized and distributed biotech model.
Total Raised: Unknown (Y Combinator backed)
Last Round: Winter 2016
Total Raised: Unknown (Y Combinator backed)
Last Round: Winter 2016
Healthcare
Healthcare
Healthcare -> Drug Discovery and Delivery
Healthcare -> Drug Discovery and Delivery
Team size: 1
Hiring: No
Team size: 1
Hiring: No
